LEF1 supports metastatic brain colonization by regulating glutathione metabolism and increasing ROS resistance in breast cancer.

Autor: Blazquez R; Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany.; Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany., Rietkötter E; Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany., Wenske B; Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany.; Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany., Wlochowitz D; Institute of Medical Bioinformatics, University Medical Center Göttingen, Georg August University, Göttingen, Germany., Sparrer D; Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany., Vollmer E; Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany., Müller G; Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany., Seegerer J; Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany., Sun X; Institute of Functional Genomics, University of Regensburg, Regensburg, Germany., Dettmer K; Institute of Functional Genomics, University of Regensburg, Regensburg, Germany., Barrantes-Freer A; Institute of Neuropathology, University Medical Center Göttingen, Göttingen, Germany.; Department of Neuropathology, University Medical Center Leipzig, Leipzig, Germany., Stange L; Department of Neuropathology, University Hospital Regensburg, Regensburg, Germany., Utpatel K; Institute of Pathology, University of Regensburg, Regensburg, Germany., Bleckmann A; Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.; Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany., Treiber H; Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.; Max Planck Institute of Experimental Medicine, Göttingen, Germany., Bohnenberger H; Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany., Lenz C; Institute of Clinical Chemistry, University Medical Center Göttingen, Göttingen, Germany.; Max Planck Institute for Biophysical Chemistry, Göttingen, Germany., Schulz M; Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany., Reimelt C; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany., Hackl C; Department of Surgery, University Hospital Regensburg, Regensburg, Germany., Grade M; Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany., Büyüktas D; Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany., Siam L; Department of Neurosurgery, University Medical Center Göttingen, Göttingen, Germany., Balkenhol M; Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany., Stadelmann C; Institute of Neuropathology, University Medical Center Göttingen, Göttingen, Germany., Kube D; Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany., Krahn MP; Internal Medicine D, University Hospital Münster, Münster, Germany., Proescholdt MA; Department of Neurosurgery, University Hospital Regensburg, Regensburg, Germany., Riemenschneider MJ; Department of Neuropathology, University Hospital Regensburg, Regensburg, Germany., Evert M; Institute of Pathology, University of Regensburg, Regensburg, Germany., Oefner PJ; Institute of Functional Genomics, University of Regensburg, Regensburg, Germany., Klein CA; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.; Project Group 'Personalized Tumour Therapy', Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany., Hanisch UK; Institute of Neuropathology, University Medical Center Göttingen, Göttingen, Germany., Binder C; Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany., Pukrop T; Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany.; Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.

Publikováno v: International journal of cancer [Int J Cancer] 2020 Jun 01; Vol. 146 (11), pp. 3170-3183. Date of Electronic Publication: 2019 Nov 11.

Nuclear LEF1/TCF4 correlate with poor prognosis in cerebral metastasis of lung adenocarcinomas

Autor: Siam, L, Bleckmann, A, Klemm, F, Rietkötter, E, Wegner, C, Kramer, F, Beissbarth, T, Rohde, V, Binder, C, Stadelmann, C, Pukrop, T

Publikováno v: 64. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC); 20130526-20130529; Düsseldorf; DOCMO.11.04 /20130521/

Objective: The transcription factors of the WNT-signaling pathway LEF1/TCF4 has been described in cerebral metastases of lung adenocarcinomas in mouse models. Their role in humans is unclear. Method: We analyzed the WNT-signaling components LEF1, TCF

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8cfcea66beb1ddaecfc37d6c2a50aad

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Cross-regulation of Aps-promoters in Lacticaseibacillus paracasei by the PsdR response regulator in response to lantibiotics.

Autor: Zhang, Qian¹ (AUTHOR), Zúñiga, Manuel² (AUTHOR), Alcántara, Cristina² (AUTHOR), Wolf, Diana¹ (AUTHOR), Mascher, Thorsten¹ (AUTHOR) thorsten.mascher@tu-dresden.de, Revilla-Guarinos, Ainhoa^1,3 (AUTHOR) ainhoa.revilla@fisabio.es

Publikováno v: Scientific Reports. 2/9/2024, Vol. 14 Issue 1, p1-14. 14p.

Nuclear LEF1/TCF4 correlate with poor prognosis but not with nuclear β-catenin in cerebral metastasis of lung adenocarcinomas.

Autor: Bleckmann, A., Siam, L., Klemm, F., Rietkötter, E., Wegner, Chr., Kramer, F., Beissbarth, T., Binder, C., Stadelmann, Chr., Pukrop, T.

Publikováno v: Clinical & Experimental Metastasis; Apr2013, Vol. 30 Issue 4, p471-482, 12p